Siegel Jesse K, Gomez Kayeromi, Bier-Laning Carol
Department of Otolaryngology-Head and Neck Surgery, Loyola University Medical Center, Maywood, Illinois, USA.
Clinical Research Office, Center for Translational Research and Education, Loyola University Chicago, Maywood, Illinois, USA.
Otolaryngol Head Neck Surg. 2025 Mar;172(3):846-852. doi: 10.1002/ohn.1043. Epub 2024 Dec 12.
Enhanced recovery after surgery (ERAS) protocols are designed to improve postoperative outcomes. In this study, we compare outcomes for patients undergoing head and neck free flap surgery at a quaternary care institution before and after an ERAS protocol was implemented.
Retrospective study.
Single quaternary care center.
Retrospective evaluation of outcomes from patients who underwent head and neck surgery with free flap reconstruction prior to ERAS (January 2018 to May 2022, baseline) with patient outcomes after implementation (June 2022 to September 2023, ERAS). Outcomes studied included length of stay (LOS), opioid utilization, postoperative emesis, readmission, and mortality.
Patients in the ERAS group had significantly lower opioid utilization (206.84 ± 217 morphine milligram equivalent vs 415.53 ± 431, P < .01) and significantly lower rates of postoperative emesis (1.74% vs 28.27%, P < .01). This difference in emesis remained significant in the subgroup of patients who underwent total laryngectomy. The decreases in opioid use and emesis remained significant in multivariate analyses controlling for demographic factors and surgery type. We found no significant decrease in LOS or mortality.
In the year after implementing an ERAS protocol for head and neck free flap surgery, we found significantly lower opioid utilization and the unique finding of lower postoperative emesis overall, including in the laryngectomy subgroup for whom emesis-induced fistula is most impactful. No difference was noted in LOS or mortality. To our knowledge, this is the first study of an ERAS protocol for head and neck surgery to show a decrease in postoperative emesis.
术后加速康复(ERAS)方案旨在改善术后结局。在本研究中,我们比较了在一家四级医疗机构实施ERAS方案前后接受头颈部游离皮瓣手术患者的结局。
回顾性研究。
单一四级医疗中心。
对在ERAS实施前(2018年1月至2022年5月,基线期)接受头颈部游离皮瓣重建手术患者的结局进行回顾性评估,并与实施后(2022年6月至2023年9月,ERAS期)的患者结局进行比较。研究的结局包括住院时间(LOS)、阿片类药物使用情况、术后呕吐、再入院率和死亡率。
ERAS组患者的阿片类药物使用量显著更低(206.84±217吗啡毫克当量 vs 415.53±431,P<0.01),术后呕吐发生率也显著更低(1.74% vs 28.27%,P<0.01)。在接受全喉切除术的患者亚组中,呕吐发生率的这种差异仍然显著。在控制了人口统计学因素和手术类型的多变量分析中,阿片类药物使用量和呕吐发生率的降低仍然显著。我们发现住院时间或死亡率没有显著降低。
在对头颈部游离皮瓣手术实施ERAS方案后的一年里,我们发现阿片类药物使用量显著降低,并且总体上术后呕吐发生率也有独特的降低,包括在呕吐导致瘘管影响最大的喉切除术亚组中。住院时间或死亡率没有差异。据我们所知,这是第一项显示头颈部手术ERAS方案可降低术后呕吐发生率的研究。